Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 3,683 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-Small Cell Lung Cancer, Small Cell Lung Cancer Clear all

Conditions: Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Head and Neck Cancer, Bladder Cancer, Non-small Cell Lung Cancer
Interventions: MGA271; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 12
States / cities: Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 7 more

Conditions: Carcinoma, Non-Small-Cell-Lung
Interventions: Temoporfin; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Non Small Cell Lung Cancer
Interventions: Pemetrexed, Carboplatin, Cisplatin, Docetaxel, Paclitaxel, stereotactic radiosurgery; Drug · Radiation
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Follicular Lymphoma
Interventions: IMT-009, Fruquintinib; Drug · Combination Product
Lead sponsor: Immunitas Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Tucson, Arizona • Denver, Colorado • Orlando, Florida + 6 more

Conditions: Non Small Cell Lung Cancer
Interventions: erlotinib, sunitinib; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Locally Advanced Non-Small Cell Lung Cancer
Interventions: Proton Radiation Therapy, Taxol, Carboplatin; Radiation · Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2011
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Lung Cancer
Interventions: Erlotinib, AZD6244, MK-2206, Sorafenib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 2
States / cities: New Haven, Connecticut • Houston, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: Bevacizumab, Carboplatin, Paclitaxel; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Carcinoma, Non Small Cell Lung
Interventions: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo, Docetaxel (Taxotere®), Dexamethasone (pre- and post-medication for docetaxel); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 913 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: BAY59-8862 (Cytotoxic Taxane); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 7
States / cities: Tucson, Arizona • Waterbury, Connecticut • Louisville, Kentucky + 4 more

Conditions: Lung Cancer, Non-small Cell Lung Cancer (NSCLC)
Interventions: Dasatinib - 1A, Afatinib - 1A, Dasatinib - 1B, Afatinib - 1B; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Carcinoma, Non-Small-Cell Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary
Interventions: talabostat, pemetrexed; Drug
Lead sponsor: Point Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 101
States / cities: Huntsville, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 84 more

Conditions: Non Small Cell Lung Cancer
Interventions: Perifosine; Drug
Lead sponsor: AEterna Zentaris; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 21
States / cities: Tucson, Arizona • Pomona, California • Aventura, Florida + 17 more

Conditions: Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Brain Metastases
Interventions: Abemaciclib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 19
States / cities: Duarte, California • La Jolla, California • San Francisco, California + 15 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Sunitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 11
States / cities: Baltimore, Maryland • City of Saint Peters, Missouri • St Louis, Missouri + 7 more

Conditions: Nonsquamous Non-small Cell Lung Cancer
Interventions: Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, Placebo matching lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 761 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 17
States / cities: Mountain View, California • New Haven, Connecticut • Fort Lauderdale, Florida + 13 more

Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Melanoma (Skin Cancer), NSCLC (Non-small Cell Lung Cancer), Pancreatic (Exocrine Only), Mix of Solid Tumors (MOST)
Interventions: blood and tissue samples, blood and tissue samples; Diagnostic Test · Other
Lead sponsor: Paradigm Health; Industry
Eligibility: 18 Years and older
Enrollment: 1,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 47
States / cities: Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 43 more

Conditions: Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: laboratory biomarker analysis, questionnaire administration; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Bladder Cancer, Breast Cancer, Head and Neck Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: docetaxel; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2008
U.S. locations: 72
States / cities: Anniston, Alabama • La Jolla, California • San Diego, California + 52 more

Conditions: Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Plasma Cell Neoplasm, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: assessment of therapy complications; Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Up to 120 Years
Enrollment: 3,571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 451
States / cities: Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 302 more

Conditions: Lung Cancer - Non Small Cell Squamous
Interventions: Ipilimumab, Placebo, Paclitaxel, Carboplatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 33
States / cities: San Diego, California • West Haven, Connecticut • Boca Raton, Florida + 29 more

Conditions: Non Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Placebo, cisplatin/carboplatin, onartuzumab, paclitaxel; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 34
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Bakersfield, California + 28 more

Conditions: Advanced Non-small Cell Lung Cancer
Interventions: Atezolizumab; Drug
Lead sponsor: Liza Villaruz, MD; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Orlando, Florida • Pittsburgh, Pennsylvania

Search by objective public record fields.

Safety Study of MGA271 in Refractory Cancer

Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer

Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Erlotinib and Sunitinib in NSCLC

Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer

A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain

Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

Pan-tumor MRD Study

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

Docetaxel in Treating Patients With Solid Tumors

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

CTP Imaging of Lung Cancer

A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)